Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 2077-2083, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soletormos, G.
Right arrow Articles by Dombernowsky, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soletormos, G.
Right arrow Articles by Dombernowsky, P.

Clinical Chemistry, Vol 39, 2077-2083, Copyright © 1993 by American Association for Clinical Chemistry

Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation

G Soletormos, V Schioler, D Nielsen, T Skovsgaard and P Dombernowsky
Department of Clinical Chemistry, Herlev Hospital, University of Copenhagen, Denmark.

Interpretation of results for CA 15.3, carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) during breast cancer monitoring requires data on intra- (CVP) and inter- (CVG) individual biological variation, analytical imprecision (CVA), and indices of individuality. The average CVP and CVG obtained from 22 healthy women were, respectively, 6.2% and 62.9% (CA 15.3), 9.3% and 86.8% (CEA), and 28.3% and 133% (TPA). The indices of individuality were all < 0.6: 0.2 (CA 15.3), 0.15 (CEA), and 0.2 (TPA). CVA depended on the concentration of the analytes. CVP and CVA determine what constitutes a significant difference between sequential results. Assuming a CVA of 11.2% (CA 15.3), 9.5% (CEA), or 11.9% (TPA), results must differ by 30%, 31%, or 72%, respectively, for P < or = 0.05. We found that CVP and CVA contribute considerably to the variation during breast cancer monitoring. Consequently, both CVP and CVA should be considered in criteria for marker evaluation. Because of low indices of individuality, conventional cutoff limits are inappropriate both for initial identification and for follow-up of breast cancer.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. J. Duffy
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Clin. Chem., March 1, 2006; 52(3): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos, A. Semjonow, P. E.C. Sibley, R. Lamerz, P. H. Petersen, W. Albrecht, P. Bialk, M. Gion, F. Junker, H.-P. Schmid, et al.
Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice
Clin. Chem., August 1, 2005; 51(8): 1342 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos and V. Schioler
Description of a Computer Program to Assess Cancer Antigen 15.3, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen Information during Monitoring of Metastatic Breast Cancer
Clin. Chem., August 1, 2000; 46(8): 1106 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos, P. Hyltoft Petersen, and P. Dombernowsky
Progression Criteria for Cancer Antigen 15.3 and Carcinoembryonic Antigen in Metastatic Breast Cancer Compared by Computer Simulation of Marker Data
Clin. Chem., July 1, 2000; 46(7): 939 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J.-C. Rymer, R. Sabatier, A. Daver, J. Bourleaud, M. Assicot, J. Bremond, J. Rapin, S. L. Salhi, B. Thirion, A. Vassault, et al.
A New Approach for Clinical Biological Assay Comparison and Standardization: Application of Principal Component Analysis to a Multicenter Study of Twenty-One Carcinoembryonic Antigen Immunoassay Kits
Clin. Chem., June 1, 1999; 45(6): 869 - 881.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.